Forte Biosciences (FBRX) Competitors $12.94 -0.95 (-6.84%) Closing price 04:00 PM EasternExtended Trading$12.93 -0.01 (-0.08%) As of 04:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock FBRX vs. OCS, OLMA, AKBA, ORKA, TYRA, PVLA, TBPH, TERN, NRIX, and GYREShould you be buying Forte Biosciences stock or one of its competitors? The main competitors of Forte Biosciences include Oculis (OCS), Olema Pharmaceuticals (OLMA), Akebia Therapeutics (AKBA), Oruka Therapeutics (ORKA), Tyra Biosciences (TYRA), Palvella Therapeutics (PVLA), Theravance Biopharma (TBPH), Terns Pharmaceuticals (TERN), Nurix Therapeutics (NRIX), and Gyre Therapeutics (GYRE). These companies are all part of the "pharmaceutical products" industry. Forte Biosciences vs. Its Competitors Oculis Olema Pharmaceuticals Akebia Therapeutics Oruka Therapeutics Tyra Biosciences Palvella Therapeutics Theravance Biopharma Terns Pharmaceuticals Nurix Therapeutics Gyre Therapeutics Oculis (NASDAQ:OCS) and Forte Biosciences (NASDAQ:FBRX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, earnings, media sentiment, dividends, valuation and profitability. Which has more risk and volatility, OCS or FBRX? Oculis has a beta of 0.29, indicating that its stock price is 71% less volatile than the S&P 500. Comparatively, Forte Biosciences has a beta of 3.03, indicating that its stock price is 203% more volatile than the S&P 500. Is OCS or FBRX more profitable? Forte Biosciences has a net margin of 0.00% compared to Oculis' net margin of -13,958.12%. Forte Biosciences' return on equity of -85.38% beat Oculis' return on equity.Company Net Margins Return on Equity Return on Assets Oculis-13,958.12% -90.31% -67.85% Forte Biosciences N/A -85.38%-72.34% Do analysts rate OCS or FBRX? Oculis presently has a consensus target price of $41.00, suggesting a potential upside of 91.95%. Forte Biosciences has a consensus target price of $68.00, suggesting a potential upside of 425.50%. Given Forte Biosciences' higher possible upside, analysts plainly believe Forte Biosciences is more favorable than Oculis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oculis 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60Forte Biosciences 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has preferable valuation and earnings, OCS or FBRX? Forte Biosciences has lower revenue, but higher earnings than Oculis. Oculis is trading at a lower price-to-earnings ratio than Forte Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOculis$780K1,195.61-$97.43M-$2.67-8.00Forte BiosciencesN/AN/A-$35.48M-$16.29-0.79 Do insiders & institutionals believe in OCS or FBRX? 22.3% of Oculis shares are held by institutional investors. Comparatively, 77.6% of Forte Biosciences shares are held by institutional investors. 5.9% of Forte Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media favor OCS or FBRX? In the previous week, Oculis had 12 more articles in the media than Forte Biosciences. MarketBeat recorded 15 mentions for Oculis and 3 mentions for Forte Biosciences. Forte Biosciences' average media sentiment score of 0.83 beat Oculis' score of 0.48 indicating that Forte Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oculis 3 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Forte Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryForte Biosciences beats Oculis on 8 of the 14 factors compared between the two stocks. Get Forte Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for FBRX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FBRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FBRX vs. The Competition Export to ExcelMetricForte BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$172.69M$3.38B$6.11B$10.47BDividend YieldN/A2.29%5.73%4.77%P/E Ratio-0.798.3264.8323.34Price / SalesN/A488.16608.74136.45Price / CashN/A46.7037.4661.86Price / Book1.5810.5512.426.81Net Income-$35.48M-$52.58M$3.32B$276.80M7 Day Performance-9.95%1.09%1.01%0.27%1 Month Performance12.72%16.09%10.75%8.31%1 Year Performance180.09%18.41%76.20%35.60% Forte Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FBRXForte Biosciences2.834 of 5 stars$12.94-6.8%$68.00+425.5%+196.2%$172.69MN/A-0.795OCSOculis2.9227 of 5 stars$18.56+5.6%$35.75+92.6%+47.5%$767.15M$780K-6.952News CoverageAnalyst RevisionHigh Trading VolumeOLMAOlema Pharmaceuticals2.5541 of 5 stars$11.06-0.4%$24.00+117.0%-8.4%$761.84MN/A-5.5970AKBAAkebia Therapeutics3.4747 of 5 stars$2.97+4.9%$6.75+127.3%+111.4%$750.36M$160.18M-17.47430News CoverageORKAOruka Therapeutics3.0317 of 5 stars$20.33+2.7%$42.00+106.6%-0.9%$741.16MN/A-7.23N/AAnalyst ForecastTYRATyra Biosciences2.184 of 5 stars$13.43-1.7%$31.86+137.2%-36.8%$728.04MN/A-7.5420High Trading VolumePVLAPalvella Therapeutics2.0234 of 5 stars$67.95+3.3%$69.27+1.9%N/A$727.51M$42.81M-5.62N/ATBPHTheravance Biopharma3.0194 of 5 stars$14.58+1.2%$23.00+57.8%+68.3%$725.70M$77.21M60.75110TERNTerns Pharmaceuticals3.9223 of 5 stars$8.43+2.4%$15.49+83.7%+6.0%$720.22MN/A-8.1140Analyst ForecastNRIXNurix Therapeutics1.8783 of 5 stars$9.95+6.1%$29.07+192.2%-63.5%$717.09M$54.55M-3.81300Earnings ReportAnalyst ForecastGYREGyre Therapeutics1.7158 of 5 stars$7.34-0.9%$18.00+145.2%-40.0%$713.68M$105.76M734.7340News CoverageGap Up Related Companies and Tools Related Companies OCS Competitors OLMA Competitors AKBA Competitors ORKA Competitors TYRA Competitors PVLA Competitors TBPH Competitors TERN Competitors NRIX Competitors GYRE Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FBRX) was last updated on 10/15/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...Banyan Hill Publishing | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Forte Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Forte Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
